Back to top

Image: Bigstock

Top Ranked Momentum Stocks to Buy for March 7th

Read MoreHide Full Article

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 7th:

La-Z-Boy Incorporated (LZB - Free Report) : This furniture products and accessories manufacturer has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.3% over the last 60 days.

La-Z-Boy’s shares gained 14.1% over the last one month against the S&P 500’s rise of 2.4%. The company possesses a Momentum Score of B.

Genocea Biosciences, Inc. : This biopharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 40.4% over the last 60 days.

Genocea Biosciences’ shares gained 44.4% over the last one month. The company possesses a Momentum Score of A.

KalVista Pharmaceuticals, Inc. (KALV - Free Report) : This pharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.3% over the last 60 days.

KalVista Pharmaceuticals’ shares gained 16.3% over the last one month. The company possesses a Momentum Score of A.

Ophthotech Corporation : This biopharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.5% over the last 60 days.

Ophthotech’s shares gained 14.4% over the last one month. The company possesses a Momentum Score of B.

See the full list of top ranked stocks here.

Learn more about the Momentum score and how it is calculated here.

Is Your Investment Advisor Fumbling Your Financial Future?

See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”

Click to get it free >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


La-Z-Boy Incorporated (LZB) - free report >>

KalVista Pharmaceuticals, Inc. (KALV) - free report >>

Published in